Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Chan Y Cheah, MBBS, FRACP, FRCPA, Kirsten Herbert, MD, BSci(Med), FRACP, PhD, Kacey O'Rourke, MBBS FRACP FRCPA, Glen Kennedy, MBBS FRACP FRCPA, Anupkumar George, MBBS FRACP FRCPA, Pasquale Fedele, MBBS, Shuh Ying Tan, MBBS, Stephen Opat, MBBS(Hons) FRACP FRCPA, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Max Wolf, MBBS, FRACP, FRCPA, Elchanan H. Januszewicz, MBBS FRACP FRCPA, Michael J. Dickinson, MBBS, FRACP, FRCPA, David A Westerman, MBBS, FRACP, FRCPA, H. Miles Prince, MBBS, FRACP, FRCPA, MD, Dennis A Carney, MBBS FRACP FRCPA, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Constantine S. Tam, MBBS, FRACP, FRCPA, MD, John F Seymour, MBBS, PhD, FRACP

Blood (2013) 122 (21): 4353.

https://doi.org/10.1182/blood.V122.21.4353.4353

Published: 2013

Journal Articles

Thalidomide Consolidation Post Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) Is Cost-Effective With Durable Survival Benefit At 5 Years Post Randomisation: Final Analysis Of The ALLG MM6 Study

Anna Kalff, MBBS, FRACP, FRCPA, Nola Kennedy, Angela Smiley, H. Miles Prince, MBBS, FRACP, FRCPA, MD, Andrew W. Roberts, MBBS, PhD, Kenneth F Bradstock, MBBS, PhD, FRACP, FRCPA, Richard De Abreu Lourenco, Andrew Spencer, MD

Blood (2013) 122 (21): 537.

https://doi.org/10.1182/blood.V122.21.537.537

Published: 2013

Journal Articles

Analysis of Patients with Common Peripheral T-Cell Lymphoma Subtypes From a Phase 2 Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma

Bertrand Coiffier, MD, Barbara Pro, MD, H. Miles Prince, MBBS, FRACP, FRCPA, MD, Francine M. Foss, MD, Lubomir Sokol, MD, PhD, Matthew Greenwood, MD, FRCPA, FRACP, Dolores Caballero, MD, Peter Borchmann, MD, Franck Morschhauser, MD, PhD, Martin Wilhelm, MD, Lauren Pinter-Brown, Swaminathan Padmanabhan, MBBS, MD, Andrei R. Shustov, MD, Jean Nichols, PhD, Susan Carroll, John Balser, PhD, Steven M. Horwitz, MD

Blood (2011) 118 (21): 591.

https://doi.org/10.1182/blood.V118.21.591.591

Published: 2011

Journal Articles

Low Dose Lenalidomide and Dexamethasone Induction Followed by Autologous Transplantation In Untreated Patients with Myeloma Is Associated with High Response Rates and Preservation of CD8, but Not CD4 or NK Cellular Immunity

Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Amit S Khot, MBBS, MD, MRCP (UK), FRCPath, Tsin Tsin, Andy Hsu, PhD, Karen Chen, Maureen Loudovaris, Paul Neeson, PhD, Dominic Wall, PhD, Rebecca Sedunary, H. Miles Prince, MBBS, FRACP, FRCPA, MD, David Ritchie, MBBS, FRACP, FRCPA, PhD

Blood (2011) 118 (21): 1862.

https://doi.org/10.1182/blood.V118.21.1862.1862

Published: 2011

Journal Articles

Lower-Dose Lenalidomide and Dexamethasone Reduces Toxicity without Compromising Efficacy In Patients with Relapsed/Refractory Myeloma, Who Are Aged ≥60 Years or Have Renal Impairment: Planned Interim Results of a Prospective Multicentre Phase II Trial

Hang Quach, MBBS, FRACP, FRCPA, MD, Liam Fernyhough, BMBS, BMediSci, FRACP, FRCPA, Ross Henderson, Gillian Corbett, Kevin Lynch, MBBS, David Ritchie, MBBS, FRACP, FRCPA, PhD, Simon J. Harrison, MD, PhD, H. Miles Prince, MBBS, FRACP, FRCPA, MD

Blood (2010) 116 (21): 1961.

https://doi.org/10.1182/blood.V116.21.1961.1961

Published: 2010

Journal Articles

Incidence, Natural History and Management of Cytomegalovirus (CMV) Dnaemia and Disease in Patients with Haematological Malignancies in the Non-Allogeneic Transplantation Setting.

John Francis Seymour, MBBS, FRACP, Ashley Ng, MBBS, BMedSci, Leon Worth, MBBS, Monica Slavin, MBBS, FRACP, H. Miles Prince, MBBS, FRACP, Karin Thursky, MBBS, FRACP

Blood (2004) 104 (11): 3837.

https://doi.org/10.1182/blood.V104.11.3837.3837

Published: 2004

NARROW

Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Thalidomide Consolidation Post Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) Is Cost-Effective With Durable Survival Benefit At 5 Years Post Randomisation: Final Analysis Of The ALLG MM6 Study

Analysis of Patients with Common Peripheral T-Cell Lymphoma Subtypes From a Phase 2 Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma

Low Dose Lenalidomide and Dexamethasone Induction Followed by Autologous Transplantation In Untreated Patients with Myeloma Is Associated with High Response Rates and Preservation of CD8, but Not CD4 or NK Cellular Immunity

Lower-Dose Lenalidomide and Dexamethasone Reduces Toxicity without Compromising Efficacy In Patients with Relapsed/Refractory Myeloma, Who Are Aged ≥60 Years or Have Renal Impairment: Planned Interim Results of a Prospective Multicentre Phase II Trial

Incidence, Natural History and Management of Cytomegalovirus (CMV) Dnaemia and Disease in Patients with Haematological Malignancies in the Non-Allogeneic Transplantation Setting.

Email alerts

ASH Publications

American Society of Hematology

Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Thalidomide Consolidation Post Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) Is Cost-Effective With Durable Survival Benefit At 5 Years Post Randomisation: Final Analysis Of The ALLG MM6 Study

Analysis of Patients with Common Peripheral T-Cell Lymphoma Subtypes From a Phase 2 Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma

Low Dose Lenalidomide and Dexamethasone Induction Followed by Autologous Transplantation In Untreated Patients with Myeloma Is Associated with High Response Rates and Preservation of CD8, but Not CD4 or NK Cellular Immunity

Lower-Dose Lenalidomide and Dexamethasone Reduces Toxicity without Compromising Efficacy In Patients with Relapsed/Refractory Myeloma, Who Are Aged ≥60 Years or Have Renal Impairment: Planned Interim Results of a Prospective Multicentre Phase II Trial

Incidence, Natural History and Management of Cytomegalovirus (CMV) Dnaemia and Disease in Patients with Haematological Malignancies in the Non-Allogeneic Transplantation Setting.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only